DGAP-News: WILEX AG successfully completes capital reduction

DGAP-News: WILEX AG successfully completes capital reduction 

DGAP-News: WILEX AG / Key word(s): Capital Reorganisation
WILEX AG successfully completes capital reduction

15.07.2014 / 07:02



WILEX AG successfully completes capital reduction

  - Reverse 4:1 share split reduces number of outstanding shares from 31.3
    million to 7.8 million

  - Conversion of shares in deposit accounts and on stock exchanges takes
    place on 18 July 2014

Munich, 15 July 2014 - WILEX AG (ISIN DE0006614720 / WL6 / FSE) today
announced that the capital reduction resolved by the Annual General Meeting
on 23 May 2014 has been implemented in a 4:1 ratio according to plan. The
entry of the capital reduction in the commercial register on 09 July 2014
reduced the number of outstanding no par value shares by 23,456,628 to
7,818,876 through consolidation of the shares in the ratio of 4:1. Prior to
this, as also resolved by the Annual General Meeting, the company's share
capital had been reduced by three shares from 31,275,507 to 31,275,504 to
obtain an even reduction ratio for the ordinary capital reduction.

This measure does not affect the percentage shareholdings of the individual
shareholders of WILEX AG. However, starting on 18 July 2014 the converted
WILEX shares will be traded on stock exchanges under the new international
securities identification number ISIN DE000A11QVV0, ticker symbol WL6.

As a result of the reverse split, the share capital of WILEX AG will be
reduced by EUR 23,456,628.00 to EUR 7,818,876.00. The difference of EUR
23,456,628.00 will be reclassified on the liabilities side of the balance
sheet of WILEX AG from subscribed capital to capital reserves. Equity and
total assets remain unchanged.

A fractional rights regulation is planned for shareholders whose number of
shares is not divisible by four on the evening of 17 July 2014.
Shareholders can decide individually whether they wish to purchase or
surrender 0.25 to 0.75 fractional rights of WILEX under the fractional
rights regulation. For this, shareholders will receive an instruction form
from their custodian bank after 18 July 2014. If shareholders do not
instruct their custodian bank to round their shareholdings up or down, the
share fractions in question will be automatically sold and the proceeds
credited to the corresponding shareholders.

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company's portfolio includes diagnostic and therapeutic
product candidates for the specific detection and targeted treatment of
various types of cancer based on antibodies and small molecules. The WILEX
subsidiary Heidelberg Pharma GmbH in Ladenburg, Germany, offers preclinical
contract research services and an antibody drug conjugate (ADC) technology
platform. More information is available at www.wilex.com.

Company contact                          IR/PR support
WILEX AG                                 MC Services AG
Sylvia Wimmer                            Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-29              Executive Director
Email: investors[at]wilex.com            Tel.: +49-89-210 228-40
Grillparzerstr. 10, 81675 Munich,        Email: katja.arnold[at]mc-
Germany                                  services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will", "should", "future", "potential" or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

End of Corporate News


15.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English                                                
Company:     WILEX AG                                               
             Grillparzerstr. 10                                     
             81675 München                                          
Phone:       +49 (0)89 41 31 38 - 0                                 
Fax:         +49 (0)89 41 31 38 - 99                                
E-mail:      info@wilex.com                                         
Internet:    www.wilex.com                                          
ISIN:        DE0006614720                                           
WKN:         661472                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
End of News    DGAP News-Service  
277851 15.07.2014                                                      
Press spacebar to pause and continue. Press esc to stop.